Menu
Intended for US HCPs Only

Administration

Loren, Actual FEIBA Patient

Help your patients utilize their time while infusing

Infusing FEIBA [Anti-Inhibitor Coagulant Complex] with a syringe pump helps your patients control the infusion rate and provides a hands-free experience.1

FEIBA is available in 3 dosage strengths1

Color-coded boxes and vial labels make it easy to identify each dose level.

FEIBA comes with a suitable volume (10 mL, 20 mL or 50 mL) of Sterile Water for Injection.

My syringe pump allows me to continue doing the things I like to do while I infuse, like gaming and tinkering. I also like to do card tricks—which are hard to do one-handed. —Loren, real FEIBA patient

Room temperature storage1

  • Vials can be stored at room temperature or in the refrigerator. Storage conditions should not exceed 25°C (77°F)
  • Store FEIBA [Anti-Inhibitor Coagulant Complex] in its original package to protect it from light
  • Avoid freezing, which may damage the diluent vial

BAXJECT II® Hi-Flow Needleless Transfer Device for easy mixing

To make reconstitution safe, fast, and easy,* FEIBA comes packaged with the BAXJECT II Hi-Flow Needleless Transfer Device. Reconstitution with the BAXJECT II Hi-Flow device requires fewer steps than the previous BAXJECT device, and it is color-coded for more intuitive reconstitution.1,4

  1. Connect the diluent vial
  2. Connect the FEIBA vial
  3. Withdraw mixed FEIBA
*As compared to needles, the BAXJECT II Hi-Flow device is needleless, and has a one-piece design.

Watch the Reconstitution Demonstration Video with BAXJECT II Hi-Flow Device

For detailed step-by-step instructions for reconstituting FEIBA with BAXJECT II Hi-Flow device, watch the video below or download the Instructions for Use.

Watch the Reconstitution Troubleshooting Video with BAXJECT II Hi-Flow Device

For additional information and troubleshooting guidance for reconstituting FEIBA with BAXJECT II Hi-Flow device, watch the video below.


BAXJECT II Hi-Flow Product Information

Rx only. For safe and proper use of this device, please refer to the Instructions for Use in the FEIBA full Prescribing Information.

NOTE: The BAXJECT II Hi-Flow device should be used only with FEIBA.

The BAXJECT II Hi-flow device is intended for use with a single vial of product and is for single use only. Therefore, reconstitution and withdrawing a second vial into the syringe requires a second BAXJECT II Hi-flow device.

Dosing Guidelines

The FEIBA Guidelines for Dosing is an educational guide for healthcare professionals only.

Learn More

Efficacy Data

Find out how FEIBA can help your patients with hemophilia A and B with inhibitors.

See the Data

Please expand for Indications and Detailed Important Risk Information

Selected Important Risk Information for FEIBA [Anti-Inhibitor Coagulant Complex]

WARNING: THROMBOEMBOLIC EVENTS

Thromboembolic events have been reported during post-marketing surveillance following infusion of FEIBA, particularly following the administration of high doses and/or in patients with thrombotic risk factors. Monitor patients receiving FEIBA for signs and symptoms of thromboembolic events.

FEIBA [Anti-Inhibitor Coagulant Complex] Indications and Detailed Important Risk Information for Healthcare Professionals

Indications for FEIBA [Anti-Inhibitor Coagulant Complex]

FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for:

FEIBA is not indicated for the treatment of bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to coagulation factor VIII or coagulation factor IX.

Detailed Important Risk Information for FEIBA [Anti-Inhibitor Coagulant Complex]

WARNING: THROMBOEMBOLIC EVENTS

The use of FEIBA is contraindicated in patients with:

Thromboembolic events (including venous thrombosis, pulmonary embolism, myocardial infarction, and stroke) can occur with FEIBA, particularly following the administration of high doses (above 200 units per kg per day) and/or in patients with thrombotic risk factors.

Infusion of FEIBA should not exceed a dose of 100 units per kg body weight every 6 hours and daily doses of 200 units per kg body weight. Maximum injection or infusion rate must not exceed 2 units per kg of body weight per minute. Monitor patients receiving more than 100 units per kg of body weight of FEIBA for the development of DIC, acute coronary ischemia and signs and symptoms of other thromboembolic events. If clinical signs or symptoms occur, such as chest pain or pressure, shortness of breath, altered consciousness, vision, or speech, limb or abdomen swelling and/or pain, discontinue the infusion and initiate appropriate diagnostic and therapeutic measures.

Hypersensitivity and allergic reactions, including severe anaphylactoid reactions, can occur following the infusion of FEIBA. The symptoms include urticaria, angioedema, gastrointestinal manifestations, bronchospasm, and hypotension. These reactions can be severe and systemic (e.g., anaphylaxis with urticaria and angioedema, bronchospasm, and circulatory shock). Other infusion reactions, such as chills, pyrexia, and hypertension have also been reported. If signs and symptoms of severe allergic reactions occur, immediately discontinue administration of FEIBA and provide appropriate supportive care.

Because FEIBA is made from human plasma it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

The most frequently reported adverse reactions observed in >5% of subjects in the prophylaxis trial were anemia, diarrhea, hemarthrosis, hepatitis B surface antibody positive, nausea, and vomiting.

The serious adverse reactions seen with FEIBA are hypersensitivity reactions and thromboembolic events, including stroke, pulmonary embolism and deep vein thrombosis.

Use of antifibrinolytics within approximately 6 to 12 hours after the administration of FEIBA is not recommended.

Please see FEIBA full Prescribing Information